Objectives To provide a comprehensive and objective summary of contraceptive failure rates
for a variety of methods based on a systematic review of the literature. Methods Medline and …

Data have demonstrated that COCs, besides offering a satisfactory and safe contraception,
offer a variety of non-contraceptive health benefits and therapeutic positive aspects. Many …

BACKGROUND: This study compared the bleeding pattern, cycle control and safety of an
oral contraceptive (OC) comprising estradiol valerate/dienogest (E2V/DNG; administered …

Objective The primary objective of the study was to clarify whether the use of the oral
contraceptive 2 mg dienogest/30 μg ethinylestradiol (DNG/EE) is associated with a higher …

Objective To evaluate the pharmacokinetics of a combined oral contraceptive (OC)
containing oestradiol valerate/dienogest (E2V/DNG) administered according to a four-phasic …

Previous attempts to replace ethinylestradiol (EE) with 17β-estradiol (E2) in combined oral
contraceptives (COCs) have proved unsatisfactory in terms of bleeding outcomes. A review …

The invention relates to the use, optionally together with oral contraception, of estradiol
valerate or 17β-estradiol in combination with 17α-cyanomethyl-17-β-hydroxyestra-4, 9-dien …

The aim of this review is to define the role of the combined dienogest (DNG)/estradiol
valerate (E2V) contraceptive pill, in terms of biochemistry, metabolic and pharmacological …

The low-dose combined oral contraceptive of ethinylestradiol 30 μg and dienogest 2 mg was
launched in Germany in 1995, and is now the most commonly prescribed oral contraceptive …

Dienogest is a hybrid synthetic gestagen which shares characteristics with 19-
nortestosterone and progesterone derivatives, and also has advantageous substance …